Home / Health / Lifileucel Sparks Hope in Advanced Melanoma
Lifileucel Sparks Hope in Advanced Melanoma
24 Oct
Summary
- Trial reported a 29.2% complete response rate in advanced melanoma patients.
- Median overall survival was not reached after over four years of follow-up.
- Company cash position expected to fund operations into late 2028.
Iovance Biotherapeutics presented significant findings from its Phase 2 IOV-COM-202 trial, evaluating Lifileucel in combination with Merck's Keytruda for advanced melanoma patients. The study involved 24 participants who received a single infusion of the cell therapy alongside Keytruda.
The trial demonstrated a compelling objective response rate of 62.5%, with nearly a third of patients achieving a complete response rate of 29.2%. Notably, the median overall survival has not yet been reached, even after a median follow-up period exceeding 50 months. Lifileucel had previously secured accelerated FDA approval in February 2024.
Chief Medical Officer Noah Berkowitz highlighted the treatment's "unprecedented efficacy and a potentially best-in-class clinical profile" for frontline advanced melanoma. Iovance is also exploring Lifileucel for soft tissue sarcomas, with initial clinical data set for presentation on October 26. The company's robust pipeline includes studies in lung and endometrial cancers as well.
As of June 30, 2026, Iovance reported approximately $304 million in cash and investments, projected to cover operational expenses through the latter half of 2028. This financial outlook, coupled with the trial's positive outcomes, has generated considerable investor interest, with shares surging significantly year-to-date.
